Please wait while the formulary information is being retrieved.
TALTZ AUTOINJECTOR (IXEKIZUMAB)
- Ankylosing spondylitis
- Moderate to severe plaque psoriasis
- Psoriatic arthritis
- Taltz Autoinjector Subcutaneous Auto-injector
- Taltz Autoinjector (3 Pack) Subcutaneous Auto-injector
- Taltz Autoinjector (2 Pack) Subcutaneous Auto-injector
- By Indication
Taltz Autoinjector 80 mg/mL subcutaneous
- Inject 1 milliliter (80 mg) by subcutaneous route every 4 weeks in the abdomen, thigh, or upper arm rotating injection sites
Taltz Autoinjector (3 Pack) 80 mg/mL subcutaneous
- Inject 1 milliliter (80 mg) by subcutaneous route every 4 weeks in the abdomen, thigh, or upper arm rotating injection sites
(2 Pack) 80 mg/mL subcutaneous
- Inject 1 milliliter (80 mg) by subcutaneous route every 4 weeks in the abdomen, thigh, or upper arm rotating injection sites
Ankylosing spondylitis
- Inject 1 milliliter (80 mg) by subcutaneous route every 4 weeks in the abdomen, thigh, or upper arm rotating injection sites
- Inject 2 milliliters (160 mg) as 2 equally divided injections by subcutaneous route once ; 4 weeks later start 1 ml (80 mg) every 4 weeks in the abdomen, thigh, or upper arm rotating injection sites
Moderate to severe plaque psoriasis
- Inject 1 milliliter (80 mg) by subcutaneous route every 4 weeks in the abdomen, thigh, or upper arm rotating injection sites
- Inject 2 milliliters (160 mg) as 2 equally divided injections by subcutaneous route once ; after 2 weeks inject 1 ml (80 mg) every 2 weeks for 6 doses, then start 1 ml (80 mg) every 4 weeks in the abdomen, thigh, or upper arm rotating inje
Psoriatic arthritis
- Inject 1 milliliter (80 mg) by subcutaneous route every 4 weeks in the abdomen, thigh, or upper arm rotating injection sites
- Inject 2 milliliters (160 mg) as 2 equally divided injections by subcutaneous route once ; 4 weeks later start 1 ml (80 mg) every 4 weeks in the abdomen, thigh, or upper arm rotating injection sites
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- None
Severe
Moderate
- None
- Active tuberculosis
Contraindicated
- Severe infection
Severe
Moderate
- Crohn's disease
- Ulcerative colitis
TALTZ AUTOINJECTOR (IXEKIZUMAB)
- Ankylosing spondylitis
- Moderate to severe plaque psoriasis
- Psoriatic arthritis
- Infection
- Dermatophytosis
- Injection site sequelae
- Nausea
- Upper respiratory infection
More Frequent
Severe
Less Severe
- Colitis
- Influenza
- Neutropenic disorder
- Conjunctivitis
- Oral candidiasis
- Rhinitis
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Angioedema
- Hypersensitivity drug reaction
- Inflammatory bowel disease
- Thrombocytopenic disorder
Less Severe
- Urticaria
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Ixekizumab
Not studied in pediatrics. No safety and efficacy data.
- 1 Day – 18 Years
- Not studied in pediatrics. No safety and efficacy data.
Ixekizumab
- Severity Level:
2
- Additional Notes: Insuff human data avail; animal data do not sugg dev tox
Contraindicated
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Precaution Exists
Ixekizumab
Insufficient human data available
General | Excretion Potential | Effect on Infant | Notes |
Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
Ankylosing spondylitis | |
M08.1 | Juvenile ankylosing spondylitis |
M45 | Ankylosing spondylitis |
M45.0 | Ankylosing spondylitis of multiple sites in spine |
M45.1 | Ankylosing spondylitis of occipito-atlanto-axial region |
M45.2 | Ankylosing spondylitis of cervical region |
M45.3 | Ankylosing spondylitis of cervicothoracic region |
M45.4 | Ankylosing spondylitis of thoracic region |
M45.5 | Ankylosing spondylitis of thoracolumbar region |
M45.6 | Ankylosing spondylitis lumbar region |
M45.7 | Ankylosing spondylitis of lumbosacral region |
M45.8 | Ankylosing spondylitis sacral and sacrococcygeal region |
M45.9 | Ankylosing spondylitis of unspecified sites in spine |
Moderate to severe plaque psoriasis | |
L40.0 | Psoriasis vulgaris |
L40.9 | Psoriasis, unspecified |
Psoriatic arthritis | |
L40.5 | Arthropathic psoriasis |
L40.50 | Arthropathic psoriasis, unspecified |
L40.51 | Distal interphalangeal psoriatic arthropathy |
L40.52 | Psoriatic arthritis mutilans |
L40.53 | Psoriatic spondylitis |
L40.54 | Psoriatic juvenile arthropathy |
L40.59 | Other psoriatic arthropathy |
0-9 | A-Z |
---|---|
L40.0 | Psoriasis vulgaris |
L40.5 | Arthropathic psoriasis |
L40.50 | Arthropathic psoriasis, unspecified |
L40.51 | Distal interphalangeal psoriatic arthropathy |
L40.52 | Psoriatic arthritis mutilans |
L40.53 | Psoriatic spondylitis |
L40.54 | Psoriatic juvenile arthropathy |
L40.59 | Other psoriatic arthropathy |
L40.9 | Psoriasis, unspecified |
M08.1 | Juvenile ankylosing spondylitis |
M45 | Ankylosing spondylitis |
M45.0 | Ankylosing spondylitis of multiple sites in spine |
M45.1 | Ankylosing spondylitis of occipito-atlanto-axial region |
M45.2 | Ankylosing spondylitis of cervical region |
M45.3 | Ankylosing spondylitis of cervicothoracic region |
M45.4 | Ankylosing spondylitis of thoracic region |
M45.5 | Ankylosing spondylitis of thoracolumbar region |
M45.6 | Ankylosing spondylitis lumbar region |
M45.7 | Ankylosing spondylitis of lumbosacral region |
M45.8 | Ankylosing spondylitis sacral and sacrococcygeal region |
M45.9 | Ankylosing spondylitis of unspecified sites in spine |
Formulary Reference Tool